Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus

被引:79
作者
Nomura, S
Shouzu, A
Omoto, S
Nishikawa, M
Fukuhara, S
Iwasaka, T
机构
[1] Kansai Med Univ, Dept Internal Med 1, Osaka 5708507, Japan
[2] Kansai Med Univ, Dept Internal Med 2, Osaka 5708507, Japan
关键词
atherosclerotic marker; nephropathy; hypertension; type 2 diabetes mellitus; valsartan;
D O I
10.1016/j.thromres.2005.04.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin II receptor blockade has been shown to have a beneficial effect on the angiopathies of hypertension and hyperglycemia in patients with type 2 diabetes. However, the effect of angiotensin II receptor blockade on monocyte and endothelial cell adhesion markers in type 2 diabetes is poorly understood. We investigated the effects of valsartan on these markers in 53 hypertensive patients with and without type 2 diabetes mellitus. Levels of monocyte activation markers (soluble CD14: 2.1 +/- 0.9 vs. 3.3 +/- 1.4 mu g/ml, p<0.01; monocyte chemotactic peptide: 392 +/- 94 vs. 489 +/- 114 pg/mL, p<0.05; and monocyte - derived microparticles: 264 +/- 98 vs. 511 +/- 128/mu L, p<0.01) and endothelial cell activation markers (soluble E-selectin: 41 +/- 11 vs. 61 +/- 20 ng/ml, p <0.001; and soluble vascular cell adhesion molecule-1: 478 +/- 82 vs. 584 +/- 101 ng/ml, p<0.01) were significantly increased in hypertensive patients with type 2 diabetes compared to normotensive controls. In addition, the concentrations of adiponectin were significantly decreased in patients with type 2 diabetes (8.1 +/- 3.1 vs. 5.2 +/- 2.5 mu g/ml, p <0.01). Regardless of the presence of diabetic complications, both systolic and diastolic blood pressures significantly decreased after valsartan administration (valsartan 80 mg/day for 8 weeks). Monocyte and endothelial cell activation markers were decreased significantly in patients with type 2 diabetes after valsartan treatment, but not in non-type 2 diabetic patients. In addition, valsartan alleviated hypoadiponectinemia in hypertensive patients with diabetes (before vs. after: 5.2 +/- 2.5 vs. 7.6 +/- 2.7 mu g/ ml, p<0.001) but did not increase adiponectin levels in the non-diabetic hypertensive group, for which the average adiponectin level was normal prior to treatment. These results suggest angiotensin II receptor blockade (valsartan) may be beneficial as an anti-atherosclerotic therapy in patients with type 2 diabetes in addition to its anti-hypertensive action. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 40 条
[1]   LEUKOCYTE-ENDOTHELIAL INTERACTIONS AND REGULATION OF LEUKOCYTE MIGRATION [J].
ADAMS, DH ;
SHAW, S .
LANCET, 1994, 343 (8901) :831-836
[2]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[3]  
BECHLAURSEN J, 1997, CIRCULATION, V95, P588
[4]   ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULES IN HUMAN-DISEASE [J].
BEVILACQUA, MP ;
NELSON, RM ;
MANNORI, G ;
CECCONI, O .
ANNUAL REVIEW OF MEDICINE, 1994, 45 :361-378
[5]   COAGULATION AND FIBRINOLYTIC SYSTEM IMPAIRMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CARMASSI, F ;
MORALE, M ;
PUCCETTI, R ;
DENEGRI, F ;
MONZANI, F ;
NAVALESI, R ;
MARIANI, G .
THROMBOSIS RESEARCH, 1992, 67 (06) :643-654
[6]   Adiponectin stimulates production of nitric oxide in vascular endothelial cells [J].
Chen, H ;
Montagnani, M ;
Funahashi, T ;
Shimomura, I ;
Quon, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) :45021-45026
[7]  
COLOTTA F, 1992, J IMMUNOL, V148, P760
[8]   E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: Possible role of oxidative stress [J].
Cominacini, L ;
Fratta Pasini, A ;
Garbin, U ;
Campagnola, M ;
Davoli, A ;
Rigoni, A ;
Zenti, MG ;
Pastorino, AM ;
LoCascio, V .
DIABETOLOGIA, 1997, 40 (05) :584-589
[9]   Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist [J].
Criscione, L ;
Bradley, WA ;
Buhlmayer, P ;
Whitebread, S ;
Glazer, R ;
Lloyd, P ;
Mueller, P ;
deGasparo, M .
CARDIOVASCULAR DRUG REVIEWS, 1995, 13 (03) :230-250
[10]   Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes - UK prospective diabetes study (UKPDS 55) [J].
Davis, TME ;
Cull, CA ;
Holman, RR .
DIABETES CARE, 2001, 24 (07) :1167-1174